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ScienceDirectMetabolic engineering and synthetic biology approaches have
prospered the field of biotechnology, in which the main focus
has been on Escherichia coli and Saccharomyces cerevisiae as
microbial workhorses. In more recent years, improving the
Gram-positive bacteria Lactococcus lactis and Bacillus subtilis
as production hosts has gained increasing attention. This
review will demonstrate the different levels at which these
bacteria can be engineered and their various application
possibilities. For instance, engineered L. lactis strains show
great promise for biomedical applications. Moreover, we
provide an overview of recent synthetic biology tools that
facilitate the use of these two microorganisms even more.
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Introduction
In the last few decades, metabolic engineering and syn-
thetic biology approaches to improve industrial applica-
tions of microbes have delivered many breakthrough
results [1]. However, most of this work has been per-
formed with the main model organisms Escherichia coli
and Saccharomyces cerevisiae. Here, we will focus on two
other workhorses in biotechnology that is the food-grade
bacterium Lactococcus lactis, and industrial chassis Bacillus
subtilis. L. lactis is indispensable in dairy and health
applications, being a production organism for antimicro-
bials, polyphenols, oral vaccines, and flavor-compound
and texturizing compound. B. subtilis is an efficientwww.sciencedirect.com metabolite and enzyme producer for various industrial
applications. Moreover, the sporulation properties of the
latter also offer opportunities for vaccine production by
expressing antigens at the surface of spores. These micro-
organisms have some unique properties, which make
them particularly suited for specific applications. Both
L. lactis and B. subtilis lack immunogenic lipopolysacchar-
ides that render them better hosts for expression of
health-related products, like antimicrobial delivery or oral
vaccines, than E. coli and other Gram-negative bacteria.
Moreover, L. lactis model strain MG1363 produces only a
low number of exoproteins and no exoproteases, while
genome-reduced B. subtilis strains [2] also lack extracel-
lular protease activity, which make these hosts excellent
enzyme producers, since the products will stably remain
in the culture supernatants.
Metabolic engineering of L. lactis
For more than 20 years, the relatively simple metabolism
of L. lactis has served as a target for metabolic engineer-
ing. The ability to metabolize a broad range of carbon
sources, high glycolytic flux and tolerance to high con-
centrations of organic acids and alcohols makes it an
excellent candidate for bioproduction of fine chemicals
and food ingredients. Rewiring the pyruvate node by
blocking competing enzymes and modifying the native
glycolytic flux via ATP (adenosine triphosphate) and
cofactor recycling, lead to strains efficiently producing
diacetyl, acetaldehyde, acetoin, and so on. The ability of
L. lactis to switch between fermentation and respiration
when hemin is present was elegantly exploited as a way to
regenerate NAD (nicotinamide adenine dinucleotide)
during acetoin and 2,3-butanediol production [3]. The
most recent studies not only obtained the highest 2,3-
butanediol level reported for L. lactis to date [4], but also
demonstrated its potential for converting dairy waste
streams into the value-added products (3R)-acetoin,
2,3-butanediol and biofuel ethanol with high yields
encouraging further bioprocess optimization [4,5].
Many engineering efforts were put in food industry-
related strain improvement, such as stress and phage
resistance [6–8]. Rerouting and overexpression of various
native and heterologous pathways in L. lactis (Figure 1a,b)
have yielded efficient vitamin, polyol, EPS (extracellular
polymeric substances), hyaluronic acid producers
(reviewed in Ref. [6]). Development of protocols for cell
propagation in emulsion droplets coupled to microfluidicsCurrent Opinion in Biotechnology 2019, 59:1–7
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Metabolic engineering strategies for the production of industrial relevant products by L. lactis and B. subtilis.
(a) Rational engineering of expression cassettes (from left to right, different colored boxes represent various promoters, RBSs, CDSs and
terminators, respectively), transporters, cofactors, or secretion machinery components. (b) Modular or combinational optimization of different
rational approaches in a multi-gene product synthetic pathway. (c) Global transcription machinery engineering (gTME) allows system-wide
pathway modification for improving the metabolic capacity or chemical tolerance. All the three levels of metabolic optimization approaches have
been done in B. subtilis, while only strategy (a) and (b) have been applied for the overexpression of products in L. lactis.and other screening methods allowed selection of strains
with higher biomass or better vitamin producers without
any targeted genetic manipulation [9,10].
Synthetic biology tools for L. lactis
Genetic engineering for strain optimization in L. lactis
has been focused for many years on traits useful to
improve industrial milk fermentations. Because of its
beneficial properties and the expanding genetic toolbox
(Table 1), L. lactis has also gained interest as an expres-
sion host for the production of heterologous proteins and
therapeutic/antimicrobial peptides [11]. Various tools
have been instrumental to enable the use of L. lactis
as a production host. Depending on the purpose, eitherCurrent Opinion in Biotechnology 2019, 59:1–7 (artificial) constitutive or inducible promoters are
employed to (over)express the gene or gene cluster of
interest. The development of inducible gene expression
systems has been extremely powerful for functional
characterization or production purposes. Various systems
have been developed, of which the NIsin-Controlled
Expression system (NICE) is mostly used [12]. Also
other systems such as Zirex (Zinc-regulated expression
system) [13] and ACE (agmatine-controlled expression)
[14] were developed that can be used alone or in com-
bination to enable sequential expression. Riboswitches
can be used as an OFF-switch to enable gene silencing
and are currently under development for L. lactis [EP
Hernandez et al., unpublished data].www.sciencedirect.com
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Table 1
Existing and novel synthetic biology tools for L. lactis
Purpose Synthetic biology tool Reference
Controlled gene expression Nisin-controlled gene expression system (NICE)
[19]
Zinc-regulated expression system (Zirex)
Agmatine-controlled expression system (ACE)
Stress-inducible controlled expression system (SICE)
pH-responsive expression (P170)
Constitutive gene expression Constitutive native promoter library [55]
Genome engineering pSEUDO. Site-specific integration based on homologous recombination [18]
Recombineering. Marker-free method for chromosomal mutations/deletions using ssDNA oligo’s [17]
Cre-loxP recombination system. Site-specific recombination system that allows multiple gene
deletions in L. lactis
[56]
CRISPR-Cas9/CRISPRi-based genome editing [57]
Improved expression host L. lactis NZ9000-4 (9k-4) with minimized genome and enhanced heterologous protein production [58]
Improved protein secretion Signal peptides (SP). A library of usp45-derived SP for efficient protein secretion [59]To introduce foreign DNA into L. lactis, electroporation is
currently the golden standard. However, DNA transfer
between two L. lactis species by conjugation was developed
[15] and a non-conjugative vertical gene transfer has been
observed as well (L Morawska, OP Kuipers, personal com-
munication). Recently, the induction of competence genes
created functional competence in L. lactis [16]. Different
gene modification systems have enabled efficient chromo-
somal mutations by using recombineering [17]. Gene inser-
tions ordeletions werefacilitatedbydoublecross-overusing
the pCS1966 plasmid that is unable to replicate and that
contains a selectable antibiotic marker and a counter-select-
able orotate transporter. This can lead to markerless dele-
tions or insertions [18]. An extensive overview of cloning
vectors and tools for gene expression/modification is pre-
sented elsewhere [19]. Currently, alternative natural
methods are being developed that open up application
options in, for example, the dairy industry. Phage contami-
nation can be the cause of significant lossofbacterial activity
in food fermentations and during the production of bio-
chemicals. Antisense RNAs against crucial bacteriophage
genes were previously used in L. lactis [20] to inhibit the
efficiency of plaquing and burst size. In these studies, there
was a limited design of these antisense RNAs, other than
cloning different parts of the genes such that the opposite
strand is transcribed as an antisense RNA. Recently, hun-
dreds of novel RNAs with putative regulatory functions
have been discovered [21] and advances in the field of
regulatory RNAs have gained tremendous insight in the
molecular mechanisms of how mRNAs can be silenced by
degradation or by blocking of the Shine Dalgarno sequence
to prevent translation, creating possibilities for a more
designer approach using regulatory RNAs as a tool to affect
gene expression. Cell penetrating peptides (CPPs) could
provide a way to deliver phosphorodiamidate morpholino
oligonucleotides (PMOs) to enable gene silencing. These
CPP–PMO’s are now allowed therapeutically [22], but can
be applied to steer fermentation during the process itself inwww.sciencedirect.com order to eliminate cell functions such as transporters or
pathways. An illustrative example of synthetic biology
making use of peptide modularity instead of DNA modu-
larity was provided by lanthionine ring shuffling of lanti-
biotics, making use of over 25 different ring, hinge, and tail
modules and a micro-alginate bead-based high throughput
screening method to obtain new-to-nature lantibiotics.
Some of the analyzed peptides possessed antimicrobial
activity and were shown to have an unprecedented host
range [S Schmitt et al., unpublished data].
Use of L. lactis for biomedical applications
An established history of safe use in the food industry
makes L. lactis an appealing organism for a number of
biomedical applications. Absence of lipopolysaccharides
and only a low number of exoproteins make it a better
delivery vehicle or expression host than E. coli and other
Gram-negative bacteria. Genetically modified (GM) L.
lactis is used to (1) prevent and treat inflammatory bowel
disease (IBD), diabetes, cancer by modulating inflamma-
tion via cytokine, anti-protease, antioxidant enzyme, anti-
bacterial, and anti-antigenic peptide secretion; (2) fight
infectious diseases and allergic reactions via modulation
of immune responses and as a safer vaccine. GM L. lactis
may even be used to deliver DNA molecules to mammalian
cells as vaccines or as a form of gene therapy [23].
Steidler et al. have established proof of principle using L.
lactis engineered to produce the anti-inflammatory cyto-
kine interleukin-10 (IL-10) to treat IBD [24]. Using
animal models, they showed that dietary administration
of engineered bacteria is therapeutically effective. An
elegant system for the containment of live GM bacteria
was designed replacing the thyA gene with an expression
cassette resulting in a strain that produces hIL-10 when is
strictly dependent on thymidine or thymine for growth
and survival. This strain was the first genetically modified
organism (GMO) to reach clinical trials [25]. To date,Current Opinion in Biotechnology 2019, 59:1–7
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ies using similar safe containment strategy. Recently, a
phase Ib/IIa study was announced to test the ability of L.
lactis secreting IL-10 and proinsulin (AG019) [26] to treat
early onset type 1 diabetes. A phase 2 clinical trial of an
oral rinse composed of a recombinant L. lactis strain
engineered to secrete the mucosal protectant human
trefoil factor hTFF1 was initiated [27]. An oral adminis-
tration of L. lactis engineered to secrete anti-TNF-alpha
nanobodies proved to be effective and safe against IBD in
a phase I trial [28].
Although the NICE system proved to be useful in many
cases, synthetic biology approaches required develop-
ment of promoters that do not involve an external inducer
and are constitutive or respond to factors which bacteria
encounter in the mammalian body (Table 1).
A resource-conserving and environmentally sustainable
production of plant natural products with health-benefi-
cial properties using microbial cell factories is an attrac-
tive alternative to plant extraction or chemical synthesis.
L. lactis was shown to be an excellent host for the
expression of plant and fungal membrane proteins and
soluble enzymes involved in polyphenol, terpenoid, and
ester synthesis [6,29]. Functional pathways for the pro-
duction of nutraceuticals resveratrol and anthocyanins
were assembled. Employment of metabolic biosensors
for malonyl-CoA allowed monitoring of intracellular pre-
cursor pool and suggested strategies to improve the
product yield [29].
Metabolic engineering of B. subtilis
In addition to L. lactis, B. subtilis has been extensively
exploited as a microbial cell factory for the overproduc-
tion of various industrially relevant products in the fields
of food, pharma, and biotechnology. In the past few
decades, numerous studies have been performed in
attempts to develop this production host into a highly
adaptable chassis with both high yields and a wide range
of products [30].
Conventional approaches for improving the production
capacity of B. subtilis include modifying the elements of
synthetic pathways, that is gene copy numbers, promo-
ters, RBSs (ribosome binding sites), CDS (coding
sequences), and terminators [31] or varying the availabil-
ity of rate-limiting components, that is the composition of
secretion machinery [32] (Figure 1a). However, these
efforts, that are based on the rational modification of
specific pathway or factors, always require a comprehen-
sive understanding of the target metabolic networks and
have limited success on strain improvement [33,34].
Metabolic engineering strategies that integrate newly
developed systems and synthetic biology approaches
have greatly facilitated the unlocking of phenotypes withCurrent Opinion in Biotechnology 2019, 59:1–7 desired cellular properties in B. subtilis [34]. Combinato-
rial pathway optimization, which enables to vary multiple
critical pathway elements, can streamline metabolic engi-
neering by reducing experimental efforts and the amount
of a priori knowledge [35] (Figure 1b). The combinatorial
engineering of promoters and RBSs [31], and non-con-
served sequences [36] demonstrated great potential in
increasing reporter gene expression levels in B.
subtilis. The divided parts of complex multi-gene product
synthetic pathways have been modularly optimized for
generating recombinant strains with improved production
of N-acetylglucosamine [37]. Moreover, simultaneous
engineering of the cell surface and the expressed targets
lead to a further enhanced secretion efficiency of a-amy-
lases in B. subtilis [38].
Global transcription machinery engineering (gTME),
which allows multiple and simultaneous perturbations
of the whole transcriptome, enables the increase of
end-products by rerouting metabolic fluxes at a top layer
of regulatory networks [1] (Figure 1c). This global opti-
mization strategy can substantially simplify the strain
enhancement design even without a complete picture
of the underlying metabolic regulatory mechanisms [39].
A variety of global transcription factors in multiple micro-
organisms have been successfully engineered to elicit
variants with improved metabolic capacity or chemical
tolerance [40]. In a recent study, the gTME-based
approach was applied for effectively and quickly unlock-
ing B. subtilis variants by randomly mutagenizing the
global N-regulator and C-regulator CodY and CcpA,
respectively. The selected best phenotype, carrying cru-
cial mutations among helix-turn-helix domains, reached a
twofold increased overproduction of b-galactosidase. Fur-
thermore, this improvement was demonstrated by the
significantly enhanced overexpression of green fluores-
cent protein, a xylanase and a peptidase [41].
Synthetic biology tools for B. subtilis
B. subtilis lends itself well to genetic manipulation due to
its ability to become naturally competent and to take up
both circular and linear forms of DNA. In addition, the
genome can easily be changed for variable purposes (e.g.
deletions, point mutations, insertions) by employing the
mechanism of homologous recombination. Nevertheless,
advances in technologies and increasing knowledge about
the characteristics of a successful bacterial production
host have driven the continuous development of useful
B. subtilis strains and genome editing tools. This makes B.
subtilis a very attractive bacterial host for academic and
biotechnological purposes.
In addition to protease deficient B. subtilis strains
(reviewed in Ref. [42]), which showed improved produc-
tion yields of heterologous proteins (Table 2), the
genome of B. subtilis has been reduced further in order
to obtain a more simplified microbial chassis that possiblywww.sciencedirect.com
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Table 2
Existing and novel synthetic biology tools for B. subtilis
Purpose Synthetic biology tool Reference
Improved expression host Protease-deficient B. subtilis strains [42]
Genome-minimized B. subtilis strains [2]
Essential gene knockdown and non-essential gene knock out libraries [45,46]
Improved genetic competence Inducible competence system to improve transformation efficiency [44]
Expression elements Bacillus BioBrick Box containing standardized vectors, reporters, promoters, epitope tags,
and optimized fluorescent proteins
[47]
A characterized phase-dependent endogenous promoter library [48]
Controlled gene expression Subtilin-regulated gene expression system (SURE) [49]
Inducer-free expression systems [50]
Genome engineering Markerless gene deletion system [51]
CRISPR-Cas9 system (pJOE8999) [52]
Databases SubtiWiki. Database of genes, proteins, metabolic and regulatory pathways. [53]
BsubCyc. Database of metabolic pathways. [54]displays even higher production yields [43]. To date, a
genome reduction of 36% has been achieved in B. subtilis
[2]. This led to two independent genome-minimized B.
subtilis strains which have been subjected to multi-omics
analyses and still display robust growth in complex
medium. To cope with the gradual decrease in genetic
competence as a consequence of genome reduction, an
inducible competence system [44] was introduced in the
minimal genome leading to a 20-fold increase in transfor-
mation efficiency compared to the reference strain B.
subtilis 168. This, in combination with the preservation of
commonly used loci for genomic integration, makes these
MiniBacillus strains attractive microbial hosts for heterol-
ogous expression. Currently, the MiniBacillus strain PG10
is exploited for the heterologous production of lantibiotic
peptides [AY van Tilburg et al., unpublished data]. A
major advantage of this lantibiotic production system in
PG10 is the lack of extracellular serine proteases which
results in the production of antimicrobial inactive precur-
sor peptides which can be activated in vitro at a later stage.
Other useful B. subtilis strains can be found in the essen-
tial gene knockdown library [45] and in two ordered and
barcoded non-essential gene knock out libraries [46]. By
providing information about gene functions, networks,
and pathways in B. subtilis, these single-gene deletion
strains can facilitate the design of tailor-made biological
systems.
In the last decade, the genetic toolbox for genome engi-
neering in B. subtilis has expanded significantly with the
development of new tools as well as improvements of
existing tools. Multiple toolboxes containing a variety of
(standardized) elements for fine-tuning gene expression
are nowadays available [47,48]. In addition, effort has
been devoted to the generation of more tightly controlled
expression systems (e.g. the subtilin-regulated genewww.sciencedirect.com expression (SURE) system [49]), as well as expression
systems that are inducer-free [50] or which do not leave
selectable markers or other scars behind [51]. Also, the
CRISPR-Cas9 system has enriched the possibilities for
genome editing in B. subtilis and other Bacillus species
[52]. By using the CRISPR-Cas9 system, disadvantages
of markerless systems can be overcome, while deletions,
mutations or insertions can easily be achieved at any place
in the genome. Furthermore, various databases have been
generated that provide a vast extent of information on the
level of DNA, proteins, regulators, and metabolites in B.
subtilis [53,54].
Conclusions and outlook
The low level of proteolytic activity, the availability of an
extensive engineering toolkit, including strictly con-
trolled promoters, and the great fermentative capacity
of L. lactis make it an attractive host for flavor, antimicro-
bial peptide and metabolite production, since heterolo-
gous enzymes needed in pathway engineering will com-
monly be stably produced. B. subtilis can grow to high cell
densities and is a great host for enzyme production,
particularly in view of recent advances to minimize its
genome reducing adverse proteolytic degradation and
undesirable phenotypes such as sporulation and biofilm
formation. A major advantage of these bacteria is also
their food-grade status, although restrictive regulations on
use of GMOs in food and environment still preclude some
exciting applications, such as gut microbiota-modulating
cultures, engineered probiotic strains or nutraceutical-
producing cultures, and oral vaccines. Recent advances
in CRISPR-Cas9 use and some foreseen medical applica-
tions, of engineered microbes might change this situation
in the near future.
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